By combining nanobodies targeting different regions of the SARS-CoV-2 Spike protein, researchers were able to protect cells from infection.
List view / Grid view
Filter the results
Scientists have developed an inhaled treatment for asthma that prevents excess mucus from building up in mice.
Understanding how Staphylococcus aureus bacteria colonises skin affected by atopic dermatitis could lead to new treatments that help prevent the spread of antibiotic resistance, say scientists.
Researchers will use the in vitro model to study how respiratory viruses, like SARS-CoV-2, cause Acute Respiratory Distress Syndrome (ARDS) and develop potential interventions.
Dr H. Michael Shepard, CEO and CSO of Enosi Life Sciences, discusses the similarities between cancer and autoimmune diseases, highlighting how this knowledge could be used to enhance treatments.
Researchers were able to eradicate breast cancer in mice when they combined CAR T cells with STING pathway agonists and immunotherapeutic antibodies.
A team has shown that synthetic molecule LAU-0901 plus aspirin-triggered NPD1 can repair brain damage in an experimental model of stroke.
Baidyanath Dash explains the two requirements for COVID-19 drug development: killing the virus and boosting immunity.
In pre-clinical trials, researchers have shown that a new vaccine could combat the dangerous effects of synthetic cannabinoids.
Anthony Finbow explains how applying microbiome-based evidence to disease modelling will enable researchers to devise more targeted treatments.
Scientists have found that the RFWD3 protein could play a role in recruiting DNA key repair and signalling factors, impacting chemotherapy.
In this article Andrew Nyborg from Horizon Therapeutics discusses why researchers are taking a second look at gout and how they are modelling the condition, which is unique to humans.
By combining natural killer cells with a new molecule called Sialyl-Lewis X, researchers were able to treat lymphoma in mice.
Researchers engineered the Disque Platform, a high-fidelity culture system, to enable them to screen drugs able to promote β cell proliferation.
Cancer researchers have created a new class of drugs to selectively target and destroy myeloid leukaemia cells with TET gene mutations.